Eduardo Rodríguez out for the year due to an inflamed heart

Eduardo Rodríguez
Getty Images
4 Comments

NEW YORK (AP) Boston Red Sox left-hander Eduardo Rodríguez will miss the entire season because of heart inflammation caused by COVID-19.

He has been on the injured list since mid-July and has not pitched this season.

“In the course of monitoring Eduardo after his return, we discovered that he was showing evidence of myocarditis, which is an inflammation of the heart, and fortunately, the severity of that complication looked mild,” Red Sox chief baseball officer Chaim Bloom said before Saturday night’s game against the Yankees.

“We were optimistic that it would resolve in short order and that we would be progressing back to pitching. As we’ve continued to monitor it, it has not resolved. It is still there,” he said.

Rodríguez was a career-best 19-6 last year with a 3.81 ERA. The Red Sox said July 7 the the 27-year-old had tested positive for COVID-19. He returned July 18, but the team said five says later that an MRI revealed an issue that turned out to be the heart condition.

“We are confident that he is going to make a full recovery and that his long-term prognosis is excellent,” Bloom said. “But the fact of the matter is that there just isn’t enough time left this season to safely ramp him back up to pitching.”

Bloom five times described the condition was “mild.” Boston received the medical update Friday night and Rodríguez told his teammates during a Zoom call on Saturday.

“Here’s one of the best pitchers in the game last year and he’s not able to perform on the field,” Red Sox manager Ron Roenicke said. “You’re more at risk when you’re older, but it hits the young pretty hard, too, at times. And Eddie just, unfortunately, is one of those guys that it hit hard, and to get to lose an entire season, it’s pretty rough on anybody.”

Rather than travel with the team, Rodríguez will return to his home in Florida.

“While the heart is is affected like this, we just can’t responsibly put any this kind of cardiovascular load on him,” Bloom said. “So once it once it resolves, we’ll be able to progress him back.”

Boston already is without left-hander Chris Sale after the staff ace had Tommy John surgery on March 30. The Red Sox rotation includes Nathan Eovaldi, left-hander Martin Perez and Ryan Weber.

“When you look out over the course of the season, it certainly makes the mountain a little higher,” Bloom said. “We will continue to obviously monitor the market and make sure we’re not walking by any opportunity to upgrade our group.”

He expects Rodríguez will make a full recovery.

“This case, while it’s something that is persistent, is not something that has that has impacted or damaged the functioning of his heart,” Bloom said. “Now myocarditis following COVID, it is obviously not something that the medical community has a lot of data on because the virus itself is new, much less in an athlete.”

More AP MLB: https://apnews.com/MLB and https://twitter.com/AP-Sports

MLB, union resume blood testing after pandemic, lockout

Scott Taetsch-USA TODAY Sports
1 Comment

NEW YORK – In the first acknowledgment that MLB and the players’ association resumed blood testing for human growth hormone, the organizations said none of the 1,027 samples taken during the 2022 season tested positive.

HGH testing stopped in 2021 because of the COVID-19 pandemic. Testing also was halted during the 99-day lockout that ended in mid-March, and there were supply chain issues due to COVID-19 and additional caution in testing due to coronavirus protocols.

The annual public report is issued by Thomas M. Martin, independent program administrator of MLB’s joint drug prevention and treatment program. In an announcement accompanying Thursday’s report, MLB and the union said test processing is moving form the INRS Laboratory in Quebec, Canada, to the UCLA Laboratory in California.

MLB tests for HGH using dried blood spot testing, which was a change that was agreed to during bargaining last winter. There were far fewer samples taken in 2022 compared to 2019, when there were 2,287 samples were collected – none positive.

Beyond HGH testing, 9,011 urine samples were collected in the year ending with the 2022 World Series, up from 8,436 in the previous year but down from 9,332 in 2019. And therapeutic use exemptions for attention deficit hyperactivity disorder dropped for the ninth straight year, with just 72 exemptions in 2022.

Overall, the league issued six suspensions in 2022 for performance-enhancing substances: three for Boldenone (outfielder/first baseman Danny Santana, pitcher Richard Rodriguez and infielder Jose Rondon, all free agents, for 80 games apiece); one each for Clomiphene (Milwaukee catcher Pedro Severino for 80 games), Clostebol (San Diego shortstop Fernando Tatis Jr. for 80 games) and Stanozolol (Milwaukee pitcher J.C. Mejia for 80 games).

There was an additional positive test for the banned stimulant Clobenzorex. A first positive test for a banned stimulant results in follow-up testing with no suspension.